Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders

NCT07205003 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2022-02-15
Last updated
2026-05-22

Condition(s) studied

Neurocognitive DisordersAlzheimer's Disease

Investigational drug(s) / intervention(s)

Assessment of carotid wall viscosity in patients with vascular dementiaAssessment of carotid wall viscosity in patients with Alzheimer's diseaseAssessment of carotid wall viscosity in patients not presenting dementia.

Assessment of carotid wall viscosity in patients with vascular dementia: Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.

Assessment of carotid wall viscosity in patients with Alzheimer's disease: Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.

Assessment of carotid wall viscosity in patients not presenting dementia.: Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.

Study summary

The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.

Unlike a purely elastic solid, which exhibits instantaneous deformation/relaxation upon application/discontinuation of a force, a viscoelastic solid is characterized, from a mechanical point of view, by a delay between the application or discontinuation of the force and deformation. Thus, at the arterial level, the elasticity of the arterial wall allows the internal diameter to increase proportionally to the blood pressure during systole. The viscous component will induce a delay in diameter restoration, resulting in a larger diameter at each pressure level during the diastolic phase compared to the systolic phase. This results in a shift between the systolic and diastolic curves of the pressure-diameter relationship, creating a hysteresis loop. From a thermodynamic point of view, while a purely elastic material fully restores the energy stored during the loading phase, viscoelastic arteries will incompletely restore this energy. Thus, the surface of the hysteresis loop reflects the energy dissipated during each cardiac cycle (WV), and the area under the loading phase curve represents the energy stored by the arterial wall (WE) during the latter. Thus, arterial wall viscosity (APV) can be expressed either as the absolute value of WV or as a function of the stored energy (WV/WE). Physiologically, this energy loss is low. Its increase could be accompanied by excessive energy dissipation, leading to increased cardiac work and cardio-circulatory decoupling. Conversely, low parietal viscosity could lead to damage to peripheral organs by excessive transmission of pulsatile energy to the periphery due to lack of damping.

Eligibility

Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age over 70 * Memory consultation consultant (neurology or geriatrics) * Brain MRI less than one year old or planned as part of the cognitive assessment performed. * Patient diagnosed with Alzheimer's disease according to DSM-5 criteria or vascular dementia according to DSM-5 criteria, or presenting a memory complaint without evidence of a dementia-related condition. * No objection from the patient or their caregiver. * Patient covered by a health insurance plan Exclusion Criteria: * Known unilateral or bilateral carotid stenosis or history of carotid surgery * Permanent CA/AF * Patient presenting with confusion * Known psychiatric illness (severe depression, psychosis, etc.) * Non-vascular, non-Alzheimer's dementia (e.g., Lewy Body Dementia, Parkinsonian Dementia, Progressive Supranuclear Palsy) * Refusal to participate * MMS less than or equal to 10 * Contraindication to performing an MRI * Any acute decompensated pathology * Patient under guardianship or curatorship

Primary outcome measure(s)

  • Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients with Alzheimer's disease — Day 1
    Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).
  • Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients not presenting dementia — enrollment visit
    Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).

Trial sites (1)

FacilityCityRegionStatus
University Rouen Hospital Rouen France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07205003 on ClinicalTrials.gov ↗ ← All trials in France